NEW YORK – Sophia Genetics said Wednesday that it has received CE marking for its Data-Driven Medicine (DDM) platform under the European Union's In Vitro Diagnostic Regulation.
The firm's cloud-based deep learning software-as-a-service platform is used to analyze genomic data alongside other clinical data, including diagnostic test results, imaging, pathology, and medical assessments, to inform drug discovery and development and treatment decisions, as well as support patient disease diagnoses.
"At Sophia Genetics, certification of our Sophia DDM Platform under IVDR builds on our track record of offering a broad set of CE-IVD applications and giving our customers confidence in knowing they are using a cutting-edge, compliant platform for their analysis needs," said Daan Van Well, the company's chief legal and compliance officer.
Earlier this year, Sophia entered into a collaboration with Microsoft and Nvidia, in which its DDM platform would be used to help commercialize a streamlined and scalable whole-genome sequencing solution for clinical research, drug discovery, and patient care.